Immunovant, Inc. (IMVT) Earnings History
Annual and quarterly earnings data from 2018 to 2025
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
Download Data
Export IMVT earnings history in CSV or JSON format
Free sign-in required to download data
Immunovant, Inc. (IMVT) Earnings Overview
As of February 28, 2026, Immunovant, Inc. (IMVT) reported trailing twelve-month net income of -$464M, reflecting -0.5% year-over-year growth. The company earned $-2.56 per diluted share over the past four quarters.
Looking at the long-term picture, IMVT's historical earnings data spans multiple years. The company achieved its highest annual net income of -$448 in fiscal 2019.
Immunovant, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to industry peers including ARGX ($923M net income, 0.4% margin), CANF (-$9M net income, -11.7% margin), AKTX (-$16M net income), IMVT has comparable earnings metrics. Compare IMVT vs ARGX →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
8 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$414M | -59.6% | -$438M | $-2.73 | - | - |
| 2024 | -$259M | -22.9% | -$270M | $-1.88 | - | - |
| 2023 | -$211M | -34.6% | -$208M | $-1.71 | - | - |
| 2022 | -$157M | -45.9% | -$156M | $-1.43 | - | - |
| 2021 | -$107M | -61.8% | -$108M | $-1.22 | - | - |
| 2020 | -$66M | -14818650.0% | -$60M | $-1.54 | - | - |
| 2019 | $-448 | +100.0% | $-450 | $0.00 | - | - |
| 2018 | -$137M | - | -$137M | $-13.67 | - | - |
See IMVT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs IMVT Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare IMVT vs AGIO
See how IMVT stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is IMVT growing earnings?
IMVT EPS of $-2.56 reflects slowing growth at -0.5%, below the 5-year CAGR of N/A. TTM net income is $-464M. Expansion rate has moderated.
What are IMVT's profit margins?
Immunovant, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are IMVT's earnings?
IMVT earnings data spans 2018-2025. The current earnings trend is -0.5% YoY. Historical data enables comparison across business cycles.